copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCL In an update from the phase III intergroup Alliance CALGB 50303 trial, treatment with frontline dose-adjusted (DA) EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) failed to improve survival outcomes compared with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for . . . Alliance CALGB 50303 compared DA-EPOCH-R with R-CHOP in a 1:1 randomization Eligible patients included untreated DLBCL (including morphologic variants centro-blastic, immunoblastic, T-cell histiocyte rich, and ana-plastic), primary mediastinal large B-cell lymphoma (PMBCL), and intravascular large B-cell lymphoma con-rmed by central pathology
CALGB-50303 Phase III Randomized Study of R-CHOP V. Dose- Adjusted . . . -c mot SECONDARY OBJECTIVES: I To compare the response rates, overall survival and toxicity of R-CHOP versus DA-EPOCH-R arge B-cell lymphoma (DLBCL) and correlate clinical parameters (toxicity, re III To assess the use of molecular profiling for pathological diagnosis V are somatically To identify new therapeutic targets using molecular
DA-EPOCH-R vs. Standard R-CHOP for Diffuse Large B-Cell Lymphoma The results of this long-awaited trial leaves R-CHOP as the standard front-line therapy for DLBCL, although many centers have adapted DA-EPOCH-R for the subtypes of primary mediastinal B-cell lymphoma and double- or triple-hit DLBCL (, , and chromosomal translocations)
The ASCO Post As reported in the Journal of Clinical Oncology by Bartlett et al, the phase III intergroup Alliance CALGB 50303 trial showed front-line DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) did not improve outcomes vs standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine
Evaluation of Dose-Adjusted EPOCH-R Compared with R-CHOP for the . . . R-CHOP remains standard of care for high-risk DLBCL subgroups when compared to DA-EPOCH-R (such as non-GCB DLBCL, DEL, and patients with IPI score > 3) Patients with DHL THL or MYC-R had greater benefit from DA-EPOCH-R compared to R-CHOP DA-EPOCH-R was associated with increased rates of AEs, including significantly more hematologic toxicity
R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of . . . The use of R-CHOP versus dose-intensified chemoimmunotherapy upfront remains controversial due to the lack of clear data to guide clinical decision-making The Alliance CALGB 50303, a large randomized phase III trial, demonstrated no difference in PFS or OS between R-CHOP and rituximab plus dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH-R) for